Status:
COMPLETED
A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection
Lead Sponsor:
Pfizer
Conditions:
Respiratory Syncytial Virus Infections
Eligibility:
All Genders
18-45 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to learn about the safety, pharmacokinetics and antiviral activity of the study medicine (called sisunatovir/RV521) for the potential treatment of respiratory syncytial vir...
Eligibility Criteria
Inclusion
- Age 18 to 45 years, inclusive
- In good health with no history of major medical conditions
- A total body weight ≥ 50 kg and a body mass index (BMI) of \>/=18kg/m2 and \</=30kg/m2
Exclusion
- Evidence of any clinically significant or currently active major medical condition
- Positive for Human Immunodeficiency Virus, active Hepatitis A, B or C test
- Significant nose or nasopharynx abnormalities
- Abnormal lung function
- History or currently active symptoms suggestive of upper or lower respiratory tract infection
Key Trial Info
Start Date :
July 19 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2017
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT03258502
Start Date
July 19 2017
End Date
October 31 2017
Last Update
July 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
hVIVO Services Ltd
London, United Kingdom